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General Introduction
Research in the field of pharmaceuticals has its most important task in the
development of new and better drugs and their successful introduction in to clinical
practice. The word 'drug' is derived from the French word ‘drogue’, which means a
dry herb. Ingeneral word a drug may be defined  as a substance used in the
prevention, diagnosis, treatment or cure of disease in man or other animal.
According to WHO, a drug may be as any substance or product which is used or
intended to be used for modifying or exploring physiological systems or pathological
states for the benefit of the recipient.
Organic chemistry and medicinal chemistry share a remarcable
common history. The relationship of medicinal chemistry to other disciplines has been
indicated by the following diagram
Chemistry and Pharmaceuticals and
biochemistry biopharmaceuticals
   Medicinal chemistry Pharmacology Internal medicine
Biology and Toxicology and
microbiology pathology
The basis of understanding in the medicinal chemistry like in an awareness of
the relationships between the chemistry of a particular compound or group of
compounds and their interactions with the body, which is known as structure activity
relationship, and the mechanism by which the compound influences the biological
system, which is known as its mode of action.
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The contribution of organic chemistry to be development of scientific
medicine in the 19th century came mainly form acyclic and carbocyclic compounds,
although the pyrazolone antipyrin (I) was introduced as an antipyretic and analgesic
in 1984 and the first barbiturate barbitone (veranol) (II) in 1903. Guttmann treated,
malaria with methylene blue in 1891, with slight success, and in 1912 he introduced
acriflavin as trypancide, it has proved to be move valuable as an antiseptic,
phenazopyridin (pyridium) (III) was introduced for the same purpose in 1926, and
although it is relatively in effective it has continued to be used since it has some
analgesic action.
The chemistry of the heterocyclic compounds is as logical as that of aliphatic
or aromatic compounds. A heterocyclic compound is one, which possess acyclic
structure with at least two different kinds of atoms in the ring. Heterocyclic
compounds have great applicability in pharmaceutics because they have specific
chemical reactivity and provides false synthon in biosynthetic process or block the
normal functioning of biological receptors. Among large number of heterocycles found
in nature, heterocycles containing nitrogen are most abundant than those containing
oxygen or sulphur owing to their wide distribution in nucleic acid instance and
involvement in almost every physiological process of plant and animals.
Most of the alkaloids which are nitrogenous bases occuring in plants and many
antibiotic including penicillin and streptomycin also contain heterocyclic ring
















 Most of the sugars and their derivatives including vitamin C, for instance, exist largely
in the form of five membered (furanoside str.) or six  membered (pyranoside str.)
ring containing one oxygen atom. Vitamin B6 (Pyridoxine) is a  derivative of pyridine
essential in amino acid metabolism, important drugs, poisons and medicines (both
natural and synthetic) such as sulphatiazole, pyrethrin, rotennone, strychnine,
reserpine, certain of the antihistaminics, the ergof alkaloids, caffeine, cocaine,
barbiturates etc. are heterocyclic.
Natural products containing heterocyclic compound such as alkaloids and
glycosides have been used since old age, as remedial agents. Febrical alkaloid
from ancient chinese drug chang shan, reserpine from Indian rouwolfia, curen
alkaloid from arrow poison codeiene, tropine and strychnine are all examples of
heterocyclic compounds. Many antibiotics like penicillin, cephalosporin, norfloxacin
etc., veterinary products like atrazine and simazine are well known examples of some
compounds of medicinal interest.
During the period 1930-1950, a large number of important drugs have been
introduced and this period is regarded as "Golden Period" of now drug discovery.
Thus starting from 1933 the first antibacterial drug prontosil leading to various
sulfa drugs; 1940- penicillin; 1945- chloroguine, an antimalarial; 1950-mothyldopa,
antidiabetic; 1958-coronary vasodilator; 1960-semisynthetic penicillin, antibacterial;
1965-trimethoprin-antimicrobial; 1967-captopril, antihypertensive. These are some
of the specific examples representing new therapeutics.
Taking in to consideration the applicability of heterocyclic compounds, the
placement of variety of substituted in these nuclei has been designed in order to
evaluate the synthesized products for their better pharmaceutical profile.
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AIM AND OBJECTIVES
In the pharmaceutical field, these have always been and will continue to be a
need for new and novel chemical inhibitors of biological function. Our efforts are
focused on the introduction of chemical diversity in the molecular frame work in
order to synthesizing pharmacologically interesting compounds of widely different
composition.
During the course of our research work, looking to the applications of
heterocyclic compounds, several entities have been designed, generated and
characterized using spectral studies. The details are as under.
1. To synthesize therapeutically active compounds like pyrazolines, isoxazoles,
cyanopyridines, cyanopyrans, cyano pyridones, cyano piperidones, cyano
pyrimidines, pyranones and Indazole bearing 3,5-dibrimo-4-methoxy
acetophenone moiety.
2. To generate several intermediates, like chalcones, cyclohexenones bearing
3,5-dibrimo-4-methoxy acetophenone moiety.
3. To characterize these products for structure elucidation using several
 spectroscopic techniques like IR, PMR and Mass spectral studies.
4. To assess the reaction and purity of the compounds were done by TLC.
5. To evaluate these products for better drug potential against different strains
of bacteria and fungi.
6. All the compounds have been sent to TAACF, southern research institute,
and USA; for antitubercular testing.
  1
"STUDIEIS ON SOME COMPOUNDS OF MEDICINAL INTEREST"
A comprehensive summary of the work to be incorporated in the thesis
entitled "STUDIEIS ON SOME COMPOUNDS OF MEDICINAL INTEREST" is
described as follow
STUDIEIS ON CHALCONE DERIVATIVES
The chemistry of chalcones containing an active keto-ethylenic linkage has
assumed importance because of their versatility in the synthesis of many
heterocyclic compounds. Furthermore, they are also associated with wide
spectrum of pharmacological activities and industrial applications. The chalcones
are reported to possess antibacterial, antiviral, agrochemical and diuretic
activities. They have been found to be applicable for photosensitive materials,
polymerization catalysts fluorescents brightening agents, pigments etc. With a
view to supplement these valid observations, it was contemplated to synthesize
some new chalcone derivatives using 3,5-dibromo-4-methoxy acetophenone with
better biological activities which have been described as under.
PART - I : STUDIEIS ON ISOXAZOLES
Isoxazole derivatives represent one of the modest class of compound
possessing wide range of therapeutic activities, such as antidepressant,
skeleton muscle relaxant, antidiabetic, anti-inflammatory, analgesic etc. With a
view to mapping better medicinal value and to evaluate its pharmacological
profile, we have synthesized some new isoxazole derivatives, which have been
described as under.









Tyep (I)           R = Aryl
The chalcones of Type - (I) have been synthesized by the condensation of
3,5- dibromo-4-methoxy acetophenone with various aromatic aldehydes.
SECTION-II : Synthesis and biological screening of 3-(3,5-Dibromo-4-
   methoxyphenyl)-5-aryl isoxazoles.
Isoxazole derivatives of Type -(II) have been prepared by the condensation
of the chalcones of Type - (I) with hydroxylamine hydrochloridie in presence of
sodium acetate in acetic acid.
PART- II : STUDIES ON PYRAZOLINES
Literature survey reveals that pyrazolines are well known for their
biological activities. These have been reported to be active as anticancer,
anticonvulsant, insecticidal, antitubercular, antibacterial and antipyretic. In order
to achieving better drug potential, we have synthesis some new pyrazoline








Type (II)         R = Aryl
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SECTION-I : Synthesis and biological screening of 1-Acetyl-3-(3,5-dibromo-
  4-methoxy phenyl)-5-aryl-4,5-dihydro-1H-pyrazoles.
Pyrazoline derivatives of Type - (III) have been synthesized by the
condensation of the chalcones of Type - (I) with hydrazine hydrate in glacial
acetic acid.
SECTION-II : Synthesis and biological screening of 4-{[ 3-(3,5-Dibromo-4-
   methoxyphenyl)-5-aryl-4,5-dihydro-1H-pyrazol-1-yl]caronyl}
   pyridines.
Pyrazoline derivatives of Type - (IV) have been synthesized by the
condensation of the chalcones of  Type - (I) with isonicotinic  hydrazide in




















Type (IV)  R = Aryl
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SECTION-III : Synthesis and biological screening of 1-(4-Chlorobenzoyl)-
    3-(3,5-dibromo-4-methoxyphenyl)-5-aryl-4,5-dihydro-1H-
    pyrazoles.
Pyrazoline derivatives of Type - (V) have been synthesized by the
condensation of the chalcones of  Type - (I) with para chlorobenzoyl hydrazide in
presence of glacial acetic acid.
PART-III : STUDIES ON INDAZOLES
Indazole derivatives have attracted considerable attention in view of their
great therapeutic importance as anticancer, ant ibacterial ,  ant i fungial,
antitubercular agents. To approach this goal, synthesis of some novel indazole
has been described as under.
SECTION-I : Synthesis and biological screening of Ethyl 4-(3,5-dibromo-











Type (V)  R = Aryl
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Cyclohexenone derivatives of Type - (VI) have been synthesized by the
cyclocondensation of chalcones of Type - (I) with ethyl acetoacetate in presence
of sodium ethoxide.
SECTION-II:Synthesis and biological screening of 6-(3,5-Dibromo-4-
 methoxyphenyl)-4-aryl- 2,3a,4,5-tetrahydro-3H-indazol-3-ones.
Indazole derivatives of Type - (VII) have been synthesized by the
cyclocondensation of the cyclohexenoes  of  Type - (VI) with  hydrazine hydrate.
PART-IV: STUDIES ON CYANO PYRIDINES
Biological importance of cyanopyridine derivatives is well known. They have
been reported to be active as an anticonvulsant, antibacterial, antitubercular,
antiinflammatory, herbicidal and antitumor. In order to develop medicinally
importnat compounds, it was considered of interest to synthesise some new



















Type (VII)  R = Aryl
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SECTION-I : Synthesis and biological screening of  2-Amino-3-cyano-6-
  (3,5-dibromo-4-methoxyphenyl)-4-aryl-pyridines.
Cyano pyridine derivatives of Type - (VIII) have been synthesized by the
condensation of the chalcones of Type - (I) with malanonitrile and ammonium
acetate.
PART-V : STUDIES ON CYANO PYRANS
Cyano pyran derivatives have attracted considerable attention in view of
their great therapeutic importance as anticonvulsant,. Antiintective, antimalerial,
cardiotonic, tranquilizer, antidiarrheal etc. Keeping this in view, it was
considered  of interest to synthesize some novel cyano pyrans, which have been
described as under.
SECTION-I : Synthesis and biological screening of 2-Amino-3-cyano-6-(3,5-
  dibromo-4-methoxyphenyl)-4-aryl-pyrans.
Cyano pyran derivatives of Type- (IX) have been synthesized by the


























Type (X)  R = Aryl
PART - VI : STUDIES ON PYRIMIDINES
Pyrimidine derivatives are biologically important products and their
synthesis and chemistry have received remarkable attention. It has been reported
that pyrimidine derivatives are associated with various biological activities, like
antifungal, antitubercular, antibacterial, herbicidal etc. This valid observation led
us to synthesise some new pyrimidines in search of agents having more
medicinally activities, which have been described as under.
SECTION-I : Synthesis and biological screening of 4-(3,5-Dibromo-4-
  methoxyphenyl)-6-aryl-pyrimidine-2-amines.
Pyrimidine derivative of Type - (X) have been prepared by the reaction of
the chalcones of Type - (I) with guanidine hydrochloride in presence of sodium
ethoxide.
PART - VII : STUDIES ON PIPERIDINONES
Piperidinone derivatives are the important class of therapeutic agents,
which have been deeply studied during search on new potential agents. They
have been found to be active as anticoagulant, anti tumor, analgesic,
antiinflammatory, herbicidal and antimicrobial agent. In light of these findings,
synthesis of some new  piperidinone derivatives has been described as under.
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SECTION-I : Synthesis and biological screening of 3-Cyano-4-(3,5-dibromo-
  4-methoxyphenyl)-6-aryl-2-oxopiperidines.
Piperidinone derivatives of Type - (XI) have been prepared by the reaction
of the chalcones of Type - (I) with cyano acetamide in presence of sodium ethoxide.
PART-VIII: STUDIES ON CYANO PYRIDONES
In view of powerful biological activities shown by cyano pyridones, like
anti tumor, antimicrobial,  analgesics, anti- inf lammatory, herbicidal and
antitubercular, it was worthwhile to synthesized some novel cyano pyridone
derivatives possessing better biological active value with least side effect, which
have been described as under.



















Type (XII)  R = Aryl
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Cyano pyridones derivatives of Type - (XII) have been prepared by the
reaction of the chalcones of Type - ( I)  with ethyl cyano acetate and
ammonium acetate.
PART - IX: STUDIES ON PYRANONES
Pyranone nucleus has been the subject of several investigators in the realm
of  potent ia l  therapeut ic  act iv i t ies  l ike  ant ibacter ia l ,  ant i tubercu lar,
antiinflammatory, herbicidal and antitumor. In order to explore the activities
associated with this nucleus, we have synthesized some new pyranones, which
have been described as under.
SECTION-I: Synthesis and biological screening of 6-(3,5-Dibromo-4-
methoxyphenyl)-4-aryl-3-phenyl-3,4-dihydro-2H-pyran-2-ones.
Pyranones derivatives of Type - (XIII) have been prepared by the reaction
of the chalcones of Type-(I) with ethyl phenyl acetate in presence of
sodium ethoxide.
The structure elucidation of the synthesized compounds has been done on
the basis of elemental analyses, Infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass spectrometry. The purity of the







Type (XIII) R = Aryl
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All the compounds also have been evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal
activity towards Aspergillus niger at a concentration of 40 ug/ml. The biological
activities of the synthesized compounds have been compared with standard
drugs.
The products have been screened for their in vitro biological assay like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37Rν
at a concentration of 1.25 ug/ml using Rifampin as a standard drug.
Signature of Guide Signature of Students
[Dr. H. S. JOSHI] [DEPEN H. VYAS]
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INTRODUCTION
The growing potent literatures of recent years demonstrate that chalcone, being
a very active synthon, variety of novel heterocycles with good pharmacological
profile can be designed. The presence of keto ethylenic linkage in general, gives
the compound a great synthetic importance.
The term "Chalcone" was first coined by Kostanecki and Tambor1, who did
pioneering work in the synthesis of natural colouring compounds. This is well
i l lustrated by benzal acetonphenone or phenyl styryl ketone or β-phenyl
acrylophenone, γ-oxo-α, γ-diphenyl-α-propylene and α-phenyl-β-benzoyl-ethylene2.
SYNTHETIC ASPECT
The most convenient method for the preparation of chalcone consists is
condensing an appropriate aryl methyl ketone with an aromatic aldehyde in
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The other condensing agent employed in several cases and sometimes with
advantages are hydrogen chloride5,6 anhydrous aluminium chloride7, weak bases
like piperidine8, boron trifluoride9, aminoacids10, organocadmium compounds11,
phosphorous oxychloride12, borax13, perchloric acid14and zinc chloride and acetic
anhydride15.
Chalcones can also be synthesised by condensing several other reagents
instead of an aldehyde and ketone.
1. Nencki reaction with cinnamic acid on an aromatic compounds16.
2. Di azo coupling of phenyl diazonium chloride with benzoyl acrylic acid17.
3. Friedel craft's cinnamoylation18.
4. Fries rearrangement of aryl cinnamates19.
REACTION MECHANISM




(A) Base catalysed :
Two alternative mechanisms were advanced for the reaction of benzaldenyde
with acetophenone in the presence of a basic catalyst.
R C CH3
O
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(B) Acid catalysed:
CH3 CO Ph + OEt
-
CH2 CO Ph + EtOH
CH2 CO Ph + PhCHO Ph CO H CH2 COPh-
Ph CO H CH2 COPh + OH2
-
Ph C OH CH2 COPhH + OH-
Ph CH OH CH2 COPh Ph CH CH COPh+ OH2
( 1 )
PhCHO OEt Ph CO H OEt
-
CH3 CO Ph + Ph COH OEt
Ph CH CH COPh OH2+
Ph CH OH COPhCH2 EtOH+
( 2 ) +






































The chemistry of chalcones has assumed importance because of their
versatility in the synthesis of many heterocyclic compounds furthermore, they are
also associated with wide spectrum of pharmacological activities and industrial
applications.
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1. Chalcones bearing an active keto-ethylenic linkage and therefore, are
reactive towards a number of reagents, yielding various heterocyclic
compounds exhibiting significant biological activities viz. pyrimidines22,23,24
cyano pyridines25, cyano pyrans26, Indazolines27, pyrazolines28,
Isoxazole29, piperidinone30, cyano pyridone31, pyranone32 etc.
2. Chalcones are intermediate compounds for the synthesis of some naturally
occuring haterocyclic compounds like flavones, flavanols, dihydroflavanols,
benzal couumarinones, anthocyanins, etc.
3. They have been useful in providing the structure of some natural products like
cyano maclurin33, eriodictoyl34, hemlock tannin35, narighenin36, phloretin37,
etc.
4. The chalcones are natural biocides38-40 and are well-known key
          intermediate in the synthesis of heterocyclic compounds possessing
          biodynamic behavior 41-44.
5. The structure of some naturally occurring pigments like chrysin, galangin,
kaempferol and quercetrol were established by their synthesis from suitable
substituted chalcones 45.
6. Chalcones and their derivatives are also found to be applicable as light
stabilizing agent46, sweetening agent47, organic brightening agent,
photosensitive material, polymerisation. catalyst, scintillators as well as
fluorescent whitening agent.
7. Chalcones are also useful for the detection of Fe(II)48 and Ca(II)49 ions in
presence of Ba and Sr, as it reacts with a number of metal ions. Trihydroxy
chalcones was used as an analytical reagent for amperometric estimation of
copper50 and for spectrophotometric study of the germanium51.
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THERAPEUTIC IMPORTANCE
Chalcone derivatives have been found to possess wide range of therapeutic

















Moreover Bekhit Adnan A. et al.80 have prepared some chalcones (I) from
4(3H)-quinazolinone derivatives which possess significant antimicrobial activity.
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Zawadowski Teodor et al.81 have synthesised a series of substituted 2-
methyl-5-hydroxy-6-acetyl-3-benzofuran carboxylic acid derivatives (II) as
antibacterial and spasmolytic agents.
Bromidge, steven marks et al.82 have prepared some indoline chalcones as
useful antagonists, anxiolytics and antidepressants. Dela Torre et al.83 have
synthesised novel [60] fullerene-flavonoid chalcones.
Moreover V. V. Mulund et al.84 have prepared some chalcones from coumarin
derivatives which possess significant antimicrobial activity. K. Bowden et al.85 have
prepared a series of substituted 3-(4-phenyl benzoyl)-chalcone/2-hydroxy chalcone
α-bromo chalcones as potential antibacterial agents. B. V. Badani and co-workers86
have reported some new chalcone derivatives as antifungal agent.
Some of the chalcones have been patented for their use as antifungal87
antimicrobial88,89 and anticancer90 agents. Aldose reductase inhibitor activity of
chalcones derivatives has been reported by Okayama et al.91 Duck sylvie92 have
synthesised chalcone derivatives (III) possessing cytotoxic activity against the
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Synthesis and insecticidal property of aryl-ω-(methyl-1,2,4-triazolimidazol-1-
yl) chalcones (IV) have been document by R. seele et al.93.
Ezio and co-workers94 have been reported chalcones having a valuable
antiproliferation activity both on sensitive cancerous cell and on cell which are
resistant to common chemotherapeutic drugs. Denny, William Alexander et al.95 have
prepared chalcones for use in antibody directed enzyme pro-drug therapy and gene
directed enzyme pro-drug therapy.
Furthermore, Tanaka, Masayuki et al.96 have prepared α,β-unsaturated
quinolinyl-ketones as inhibitor of inter-leukinone production. Sreenivasulu. Sharma97
have reported dichalcones with 100% antifeedant activity. Bradsher et al.98 and
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Chalcones have been proved to be an important intermediate for the
synthesis of many heterocyclic compounds in organic chemistry. These facts
prompted us to synthesise some novel chalcones derivatives bearing 3,5-
dibromo-4-methoxy acetophenone moiety, in order to achieving better therapeutic
agents, this study is described in the following parts.
PART-I : STUDIES ON ISOXAZOLES
PART-II : STUDIES ON PYRAZOLINES
PART-III : STUDIES ON INDAZOLES
PART-IV : STUDIES ON CYANOPYRIDINES
PART-V : STUDIES ON CYANOPYRANS
PART-VI : STUDIES ON PYRIMIDINES
PART-VII : STUDIES ON PIPERIDINONES
PART-VIII : STUDIES ON CYANOPYRIDONES
PART-IX : STUDIES ON PYRANONES
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INTRODUCTION
The five membered heterocyclic compounds containing nitrogen and oxygen
atoms have so far been synthesised for their potentials in exhibiting some kind of
activities and also for correlating it with its structure. The structural moieties such as
Isoxazoles have been found to be responsible for their various physiological,
biological and agricultural activities.
The structure of an isoxazole was first constructed by claisen in 1988, from
the reaction of 1,3-diketone with hydroxylamine100.
Subsequently, Quilico have developed the isoxazole chemistry by reaction of
isoxazole101 from nitrile-N oxides and unsaturated compounds.
SYNTHETIC ASPECT
Isoxazoles can be prepared by various methods which are described as
under.
1. Fanshave and crawely102  prepared isoxazole from α,β-unsaturated carbonyl










CH R1 + NH2OH  HCl
KOH
.
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2. It may be prepared by the reaction between α,β-diketones and hydroxylamine
hydrochloride103.
3. Schmidt and widmann104 synthesized diethyl-α-methyl isoxazole-β,γ-
dicarbonate by adding diethyl-β-diacetyl succinate to red fuming HNO3 at
0- 5oC.
4. Dawood, Kamal et al.105 prepared isoxazole derivatives from enamino
nitriles.
5. It may also be prepared by the reaction of dibromo chalocone with
hydroxylamine hydrochloride106.
6. It has been reported that cycloaddition reaction of the nitril-oxide one
performed with simple stereogenic propargylic ethers, to give isoxazoles107.
7. Tayde, V. B. et al.108 synthesized some new 3,5-diaryl isoxazoles by the
reaction of 2-aryl actophenones with hydroxylamine hydrochloride in
presence of alkali.
8. J. F. Hansen and S. A. Strong109 isolated isoxazoles from α,β-unsaturated
ketones and N-bromosuccinamide.
Recently, Beatrice et al.110 prepared isoxazoles by the one pot reaction   under
microwave irradiation. S. Balaic et al.111 have been reported the reaction of 1,3-
diketones with hydroxylamine hydrochloride on sil icagel under microwave
irradiation to generate isoxazole derivatives.
THERAPEUTIC IMPORTANCE
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Moreover, antiinfilammatory activity of some newly synthesized isoxazole have
been reported by A. Ando130. Teley Hand co-workers131 and Mishra et al.132
synthesized isoxazole and reported their analgesic and anti-inflammatory activities.
Inai, Masato Shi et al.133 also synthesized isoxazole derivatives possessing
analgesic activity.
Vekariya, N. A. et al.134  synthesised isoxazoles (I) and tested their
anticancer activity. Burk Robert M. et al.135  have prepared isoxazoles as
prostaglandin F2α  antagonists.
Wang, Gary, T. et al.136 synthesised aryl phenyl heterocycle sulfide
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Dyke, Hazel Joun et al.137 have prepared quinazolinedione derivatives as
inosine 5'-monophosphate dehydrogenase (IMPDH) inhibi tors for use in
pharmaceutical compositions. Momose, Yu; Mackawa et al.138 reported isoxazoles
derivatives (III) for prevention and treatment of diabetes.
Diana, Guy D. et al.139 documented some isoxazole derivatives as
antipicor-navirus as agents. Misra, Raj, N et al.140 prepared isoxazoles (IV) as
inhibitors of cyclin dependent kinases.
Shionogi et al.141 synthesised and tested isoxazole derivatives (V) as
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G. Daidone, D. Roffa et al.142 synthesized some novel 3-(isoxazol-3-yl)-
qu inoza l in-4- (3H)-one der ivat ives and tes ted for  the i r  ana lges ic  and
antiinflammatory activities as wel as for their acute toxicity and ulcerogenic effect.
Joshi et al.143 synthesized some isoxazole (VI) derivatives as antitubercular and
antimicrobial agents.
Antitumor activitity144,145of isoxazole derivatives have been reported by  S.
Rung and M. Scobie.
Aicher Thomas D. et al.146 reported isoxazoles as hypoglycemic agents. Kim
Sujeone et al.147 demonstrated isozazoles linkage for replacement of nucliotide
phophodiester. Nyitrai et al.148 reported isoxazole have remarkable anxiolytic and
antihy pertensive effect.
Sezer Ozkhan et al.149 have prepared isoxazoles and tested their
insecticidal activity. Some potent herbicidal activity of isoxazoles found by Reddy et
al.150 Gudhadhe et al.151 reported antimicrobial activity of isoxazole derivative.
Parikh et al.152 have been synthesized isoxazole and evaluated for their
antimicrobial activity. Some isoxazole derivatives have been patented for their use
as herbicides and fungicides 153 for the treatment of prophylaxis of autoimmune or
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With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of isoxazoles bearing 3,5-dibromo-4-
methoxy acetophenone moiety which have been described in Section-II.
SECTION-I :  SYNTHESIS AND BIOLOGICAL EVALUTION OF (2E)-1-(3,5-
   DIBROMO-4-METHOXYPHENYL)-3-ARYL-PROP-2-EN-1-ONES.
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUTION OF 3-(3,5-DIBROMO-
   4-METHOXYPHENYL)-5-ARYL-ISOXAZOLES 3- (3,5-DIBROMO-4-
METHOXY PHENYL)-5-ARYL -ARYLISOXAZOLE.
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF  (2E)-1-(3,5-DIBROMO-4-
METHOXYPHENYL)-3-ARYL-PROP-2-EN-1-ONES
Chalcone derivatives occupy a unique place in the field of medicinal
chemistry due to wide range of biological activities exhibited by them, prompted by
these facts, the preparation of chalcones of types (I) have been carried out by
condensation of 3,5-dibromo-4-methoxy acetophenone with various aldehydes.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
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Gram positive bacteria : Bacillus megaterium
Bacillus subtillis
Gram negative bacteria : Escherichia coli
Proteus vulgaris
Fungi : Aspergillus niger
Concentration : 40  µg/ ml
Sovent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzyl penicillin,
Ampicillin, Norfloxacin,
Griseofulvin
The results of antibacterial screening were compared with standard drugs viz.
Amoxicillin, Benzyl penicillin, Ampicillin, Norfloxacin and the results of antifungal
testing was compared with Griseofulvin. The zones of inhibition have been
measured in mm.
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2925 2975-2950 156
-CH3 C-H str.(sym.)    2819 2880-2860    “
C-H def.(asym.)    1467 1470-1435    “
C-H def.(sym.)    1365 1390-1370    “
Aromatic C-H str.    3060 3090-3030 157
C=C str.    1467 1540-1480    “
   1166 1125-1090    “
   1053 1070-1000    “
Halide C-Br str.    646 600-500 156
Ether C-O-C str.(sym)    1215 1275-1200    “
   1053 1075-1020    “
Vinyl CH=CH- str.     3411 3050-3000     “
Chalcone C=C str.     1569 1580-1550 157
C=O str.     1651 1672-1652    “


























Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.06 6H singlet N-(CH3)2
      2. 3.94 3H singlet Ar-OCH3
      3. 7.17-7.22 1H doublet -CHa
      4. 7.78-7.83 1H doublet -CHb










NMR SPECTRAL STUDIES OF (2E)-1-(3,5-DIBROMO-4-METHOXYPHENYL)-3-
(4-N,N-DIMETHYLAMINOPHENYL)-PROP-2-EN-1-ONE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF  (2E)-1-(3,5-DIBROMO-4-
METHOXYPHENYL)-3-ARYL-PROP-2-EN-1-ONES
(A) Synthesis of 3,5-Dibromo-4-hydroxy acetophenone
4-Hydroxy acetophenone (1.36gm, 0.01mol) dissolved in glacial acetic acid
and water(75ml) then it  was stirred at room temerature to make a homogeneous
solution. Then bromine(1.6gm, 0.01mol) in gacial aceticc acid was added drop wise
to a solution and stirred for 1hr at room tempature. The resuting solution was then
poured over crushed ice. The seperated solid was filtered and crystallized from
methanol Yield 80%, m. p. 1810C, Anal. Calcd. for C8H6Br2O2 : Require: C, 32.69,
H, 2.06; Found: C, 32.75, H, 2.12%.
(B) Synthesis of 3,5-Dibromo-4-methoxy acetophenone
To a solution of 3,5-dibromo-4-hydroxy acetophenone (2.93gm, 0.01 mol) in
a25ml methanol, dimethyl sulfate (2.5gm, 0.02 mol) was added dropwise.The
resulting mixture was stirred for 1hr at room temprature. Then the content was poured
on to crushed ice, this the solid seprated was filterated and crystallized from ethanol
Yield 70%, m. p.  900C, Anal. Calcd. for C9H8Br2O2  Require : C, 35.10, H, 2.62;
Found: C, 32.20, H, 2.72%.
(C) Synthesis of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-(4-N,N-
dimethyl aminophenyl)-prop-2-en-1-one
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Dissolve 3,5-dibromo-4-methoxy acetophenone (3.07gm, 0.01mol) in (25 ml
methanol) to this add 4-N,N-dimethylamino benzaldehyde (1.49gm, 0.01mol)in (25
ml methanol) and was stirred at room temperature for 24hrs. in prasence of catalytical
amount of 40% KOH. The resulting solution was poured on crushed ice, thus the
solid seprated was filterated and crystallized from ethanol, Yield 65%, m. p. 1450C,
Anal. Calcd. for C18H17Br2NO2 Require : C, 49.23, H, 3.90, N, 3.19 ; Found: C,
49.35, H, 3.96, N, 3.17%.
Similarly, other compound were prepared. The physical data are recorded in
Table No. 1
(D) Biological screening of (2E)-1-(3,5-dibromo-4-methoxyphenyl)-3-aryl-
prop-2-en-1-ones
(a) Antibacterial activity
The purified products were screened for their antibacterial activity using
cup-plate agar diffusion method. The nutrient agar broth prepared by the usual method
was inoculated aseptically with 0.5 ml of 24 hrs. old subcultures of Bacillus
magaterium, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa
in separate conical flasks at 40-500C and mixed well by gentle shaking. About25 ml
content of the flask was poured and evenly spreaded in a petridish (13 cm diameter)
and allowed to set for 2 hrs. The cups (10 mm diameter) were formed by the help of
borer in agar medium and filled with 0.04ml (40mg) solution of sample in DMF.
The plates were incubated at 370C for 24 hrs. and the control was also
maintained with 0.04ml of DMF in a similar manner and the zone of inhibition of the
bacterial growth were measured in millimeter and recorded in Graphical Chart No. 1
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(b) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate agar
diffusion method. The culture was maintained on sabourauds agar slants sterilized
sabourauds agar medium was inoculated with 72 hrs. old 0.5ml suspension of
fungal spores in a separate flask. About 25ml of the inoculated medium was evenly
spreaded in a petridish (13cm diameter) and allowed to set for 2 hrs. the cups (10mm
diameter) were punched. The plates were incubated at 300C for 48 hrs. After the
completion of incubation period, the zone of inhibition of growth n the form of
diameter in mm was measure. Along the test solution in each petridish one cup was
filled up with solvent, which acts as control. The zone of inhibition of test solution are
recorded in Graphical Chart No. 1
Studies on some comp. of med. interest
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SECTION II
SYNTHESIS AND BIOLOGICAL SCREENING OF 3- (3 ,5-DIBROMO-4-
METHOXYPHENYL)-5-ARYL-ISOXAZOLES
Isoxazole have been reported to have various pharmacological activities like
antibacterial, antifungal, insecticidal etc. In order to achieving better drug potency.
We have prepared isoxazole derivatives of type (II) by the cyclocondensation of (2E)-
1-(3-5-dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-1-ones of type(I) with
hydroxylamine hydrochloride in presence of sodium acetate in glacial aletic acid.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass Spectrometry.
All the compounds have been evaluated for their invitro biological assay like
antibacterial activity towards gram positive and gram-negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
















Type (I)    
     
Type (II)R = Aryl
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)     2929 2975-2950 156
-CH3 C-H str.(sym.)     2835 2880-2860    “
C-H def.(asym.)     1421 1470-1435    “
C-H def.(sym.)     1373 1390-1370    “
Aromatic C-H str.     3053 3090-3030 157
C=C str.     1521 1540-1480    “
    1116 1125-1090    “
Halide C-Br str.     619 600-500 156
Ether C-O-C str.(sym)     1255 1275-1200    “
    1029 1075-1020    “
Isoxazole C=C str.     1531 1580-1550 157
C=N str.     1471 1470-1460    “
N-O str.     883 810-850    “











































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.83 3H singlet Ar-OCH3
      2. 3.94 3H singlet Ar-OCH3
      3. 7.52 1H singlet Isox-CHa










NMR SPECTRAL STUDIES OF 3-(3,5-DIBROMO-4-METHOXYPHENYL)-5-(4-
METHOXYPHENYL)ISOXAZOLE
Studies on some comp. of med. interest




























































Studies on some comp. of med. interest
    Isoxazole.....
43
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL OF 3-(3,5-DIBROMO-4-METHOXYPHENYL)-5-
ARYL-ISOXAZOLES
(A) Synthesis of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-1-
ones
See Part-I, Section-I (C).
(B) Synthesis of 3-(3,5-Dibromo-4-methoxyphenyl)-5-(4-methoxyphenyl)-
isoxazole
(2E)-1-(3-5-Dibromo-4-methoxyphenyl)-3-(4-methoxyphenyl)-prop-2-en-1-one
(4.39 gm, 0.01 mol) in ethanol (25 ml) and anhydrous sodium acetate (0.739gm,
0.01 mol) dissolved in minimum amount of acetic acid. Mix this two solution and add
hydroxylamine hydrochloride(0.59 gm, 0.01 mol). The reaction mixture was refluxed
on oilbath for 7-8 hrs. The products was isolated and crystallized from ethanol. Yield
65 %, m.p. 1150C  Anal. Calcd. For C17H13Br2NO3 Requires ; C, 46.50; H, 2.98;
N, 3.19; Found C, 46.55, H, 3.03; N, 3.17%.
Similarly, other 3-(3,5-dibromo-4-methoxyphenyl)-5-aryl-isoxazoles were
prepared. The physical data are recorded in Table No.3.
(C) Biological screening of 3-(3,5-dibromo-4-methoxyphenyl)-5-aryl-
Isoxazoles
Antimicrobial testing were carried out as described in Part-I Section-1 (D).
The zones of inhibition of test solution are reported in Graphical Chart No 3.
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2- Pyrazoline consist a unique class of nitrogen containing five member
heterocycle. Pyrozolines have attracted attention of medicinal chemists for both with
regard to heterocyclic chemistry and the pharmacological activities associated with
them. Pyrazoline have been studied extensively because of ready accessibility,
diverse chemical reactivity, broad spectrum of biological activity1 and varieties of
industrial applications2.
The chemistry of pyrazoline was reviewed by Jarobe in 1967.
SYNTHETIC ASPECT
Different methods available in literature for the preparation of pyrazolines are
as under.
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2. Epoxydation of chalcones gave epoxy ketones which on reaction with
pyrazoline or phenyl pyrazoline to give substituted pyrazolines derivatives4.
3. 2-Pyrazolines can also be synthesised by the reaction of chalcone dibromide
with hydrazine hydrate5.
4. Dipolar cycloaddition of nitrilamines to dimethyl fumarate, fumaro nitrile and
the N-aryl maleimides yields the corresponding pyrazolines6.
5. 2- Pyrazolines can also be obtained through cycloaddition of diazomethane
to appropriately substituted chalcones7.
Recently, microwave assisted synthesis of 2-pyrazolines described by S.
Paul et al.8 and Dandia Anshu et al.9
REACTION MECHANISM
The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate10
THERAPEUTIC IMPORTANCE


































































Sonave S. S. et al.27  have synthesised 3-(2'-acetoxy-4'-methoxyphenyl)-5-
(substituted phenyl)-pyrazolines (I) and tested their antimicrobial activity.
H. S. Joshi, et al.28 synthesised 1-substituted -3-aryl-5-(3'-bromophynel)-

























Grazia Momolo M. et al.29 have synthesised 5-aryl-1-isonicotinoyl-3-(pyridin-
2-yl)-4,5-dihydro-1H-pyrazoline derivatives (III) and reported as antimicrobial and
antituberculosis agent.
R. H. Udapi et al.30 have sysnthesised 2-(6-methoxynaphthyl)-propionic acid
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V. S. Jamode et al.31 have prepared and  screened their antimicrobial
activity of 1- isonicotinoyl carboxamido-2-pyrazolines (V).
Further more, Tsuboi et al.32 have reported some new (phenyl amino
carbonyl)-pyrazoline (VI) as an insecticides and at 40% concentration shows 100%
mortality of spodostera litura larve after seven days.
Parekh H. H. et al.33 have also synthesised some new pyrazolines
derivatives as an antimicrobial agent.
Sharan and co-workers34 have reported antibacterial and antiinflammatory
activities of pyrazolines. Bala Krishana Kaluraya and co-workers35 have documented
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Stevenson et al.36 have synthesised pyrazolines as selective insecticides.
Simsek, Rahime et al.37 prepared acetyl pyrazoline and reported as antifungal and
antimicrobial agents.
Ehen- DMT et al.38 have described N-substituted pyrazoline type insecticides.
Tanka Katsiuhori39 have patented pyrazoline derivatives as herbicides. Uhlendrot
Jouchim and co-workers40 synthesised pyrazolines as an antiinflammatory and
allergy inhibitors. Some novel pyrazoline containing bisphosphonate ester was
sythesised and reported as antiinflamatory and antiarithritic agents by Nugent
Richard A. et al.41
B. Shivarama et al.42 have synthesis  phenyl pyrazolines as antibacterial
activity. Gineinah et al.43 have synthesised of phenyl pyrazolines as anticonvulsant
agents. Gevariya. Harsukh et al.44 have synthesised of some novel unsymmetrical
pyrazolines as antitubercular agent.
Thus, significant biological properties associated with pyrazoline derivatives
have aroused considerable interest to design the compounds with better drug
potentials and to study their pharmacological profile, the synthesis and therapeutics
evaluation of them, have been described as under.
SECTION  : 1 PREPARATION AND BIOLOGICAL SCREENING OF 1-
ACETYL-3-(3,5-DIBROMO-4-METHOXYPHENYL)-5-ARYL-
4,5-DIHYDRO-1H-PYRAZOLES.
SECTION : 2 PREPARATION AND BIOLOGICAL SCREENING OF 4-{[3-
(3,5-DIBROMO-4-METHOXYPHENYL)-5-ARYL-4,5-DIHYDRO-
1H-PYRAZOL-1-YL]CARBONYL}PYRIDINES.
SECTION  : 3 PREPARATION AND BIOLOGICAL SCREENING OF 1-(4-
CHLOROBENZOYL)-3-(3,5-DIBROMO-4-METHOXYPHENYL)-
5-ARYL-4,5-DIHYDRO-1H-PYRAZOLES.




SYNTHSIS AND BIOLOGICAL SCREENING OF 1-ACETYL-3-(3,5-DIBROMO-4-
METHOXYPHENYL)-5-ARYL-4,5-DIHYDRO-1H-PYRAZOLES
           The broad spectrums of pharmacological properties have been demonstrate
by the pyrazoline nucleus. Inspired by these facts, novel pyrazoline derivatives of
Type (III) have been investigated. The (2E)-1-(3,5-dibromo-4-methoxyphenyl)-3-aryl-
prop-2-en-1-ones of type (I) when treated with hydrazine hydrate in acetic acid yielded
1-acetyl-3-(3,5-dibromo-4-methoxyphenyl)-5-aryl-4,5,dihydiro-1H pyrazoles,
derivatives of type (III).
The structure elucidation of synthesized compounds have been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
















Type(I) Type(III)R = Aryl
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2970 2975-2950 45
-CH3 C-H str.(sym.)    2860 2880-2860   “
C-H def.(asym.)    1440 1470-1435   “
C-H def.(sym.)    1398 1390-1370   “
Aromatic C-H str.    3070 3090-3030 46
C=C str.    1566 1540-1480   “
   1126 1125-1090   “
   1035 1070-1000   “
Halide C-Br str.    590 600-500 45
Ether C-O-C str.(sym)    1269 1275-1200   “
   1045 1075-1020   “
Carbonyl C=O str.    1645 1680-1652 46
Pyrazoline C=N str.    1585 1627-1580   “













































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
Studies on some comp. of med. interest
pyrazoline.....
62
Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 2.83 3H singlet -COCH3
      2. 2.91 6H singlet -N(CH3)2
      3. 3.04-3.12 1H        double-doublet -CHa
      4. 3.57-3.66 1H        double-doublet -CHb
      5. 3.92 3H singlet Ar-OCH3
      6. 5.50-5.56 1H        double-doublet -CHc














NMR SPECTRAL STUDIES OF 1-ACETYL-3-(3,5-DIBROMO-4-METHOXY
PHENYL)-5-(4-N,N-DIMETHYLAMINOPHENYL)-4,5-DIHDRO-1H-PARAZOLE


























































































SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ACETYL-3-(3,5-DIBROMO-
4-METHOXYPHENYL)-5-ARYL-4,5-DIHYDRO-1H-PYRAZOLES
(A) Synthesis of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-
1-ones
See Part-I, Section-I (C).
(B) Synthesis of 1-Acetyl-3-(3,5-dibromo-4-methoxyphenyl)-5-(4-N,N-
dimethylaminophenyl)-4,5-dihydro-1H-pyrazole
A mixture of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-(4-N,N-dimethyl
aminophenyl)-prop-2-en-1-one. (4.39 gm, 0.01 mol) in methanol (25 ml) and
hydrazine hydrate (0.5gm, 0.01 mol) was refluxed for 8 hrs. The product was
isolated and crystallized from ethanol. Yield 68%, m.p. 1780C, Anal. Calcd. for
C20H21Br2N3O3; Requires: C, 48. 51; H, 4.27; N, 8.49 %;  Found: C, 48.55; H,
4.32; N, 8.47 %.
Similarly, other 1-Acetyl-3-(3,5-dibromo-4-methoxyphenyl)-5-aryl-4,5-
dihydro-1H-pyrazoles were prepared. The physical data and recorded in Table No.3
(C) Biological screening of 1-Acetyl-3-(3,5-dibromo-4-methoxyphenyl)-5-
aryl-4,5-dihydro-1H-pyrazoles
Antimicrobial testing were carried out as described in Part-I Section-I(D). The
zones of inhibition of test solutions are recorded in Graphical Chart No.3
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 SECTION - II
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-{[3-(3,5-DIBROMO-4-
METHOXYPHENYL)-5-ARYL-4,5-DIHYDRO-1H-PYRAZOL-1-YL] CARBONYL}
PYRIDINES
Pyrazoline have been found to be associated with broad spectrum of
biological activities. Hence, it was thought of interest to synthesized 4-{[3-(3,5-
dibromo-4-methoxyphenyl)-5-aryl-4,5-dihydro-1H-pyrazol-1-yl]carbonyl}pyridines of
type-(IV) from (2E)-1-(3,5-dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-1-ones of
type-(I) by the cyclo condensation with isoniazide shown as under.
The structure elucidation of synthesized compounds have been done on the
basis of elemental analyses, Infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
















Type(I) Type(IV)R = Aryl
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2923 2975-2950 45
-CH3 C-H str.(sym.)    2852 2880-2860   “
C-H def.(asym.)    1440 1470-1435   “
C-H def.(sym.)    1346 1390-1370   “
Aromatic C-H str.    3072 3090-3030 46
C=C str.    1523 1540-1480   “
   1099 1125-1090   “
   1053 1070-1000   “
Halide C-Br str.     651 600-500 45
Ether C-O-C str.(sym)    1257 1275-1200   “
   1053 1075-1020   “
Carbonyl C=O str.    1668 1680-1652       46
Pyrazoline C=N str.    1606 1627-1580         “















































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.17-3.23 1H        double-doublet -CHa
      2. 3.82-3.90 1H        double-doublet -CHb
      3. 3.96 3H singlet Ar-OCH3
      4. 5.82 1H        double-doublet -CHc










NMR SPECTRAL STUDIES OF 4-{[3-(3,5-DIBROMO-4-METHOXYPHENYL)-5-
PHENYL-4,5-DIHYDRO-1H-PYRAZOL-1-YL]CARBONYL}PYRIDINE

















































































SYNTHESIS AND BIOLOGICAL SCREENING OF 4-{[3-(3,5-DIBROMO-4-
METHOXYPHENYL)-5-ARYL-4,5-DIHYDRO-1H-PYRAZOL-1-YL]CARBONYL}
PYRIDINES
(A) Synthesis of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-1-
ones
See Part-I, Section-I (C).
(B) Synthesis of 4-{[3-(3,5-Dibromo-4-methoxyphenyl)-5-phenyl-4,5-
dihydro-1H-pyrazol-1-yl]carbonyl}pyridine
A mixture of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-phenyl-prop-2-en-1-one.
(3.96gm, 0.01 mol) in a 25 ml of glacial acetic acid and isoniazide (1.47gm, 0.01
mol) was refluxed for 8 hrs. The resulting content was poured on to crushed ice. The
product was isolated and crystallized from ethanol. Yield 70%, m.p. 1390C, Anal.
Calcd. for C22H17Br2N3O3; requires: C, 51.29; H, 3.33; N, 8.16; Found: C, 51.35;
H , 3.42; N, 8.14 %.
Similarly, other 4-{[3-(3,5-dibromo-4-methoxyphenyl)-5-aryl-4,5-dihydro-1H-
pyrazol-1-yl]carbonyl}pyridines were prepared. The physical data and recorded in
Table No.4
(C) Biological screening of 4-{[3-(3,5-Dibromo-4-methoxyphenyl)-5-ar yl-4,5-
dihydro-1H-pyrazol-1-yl]carbonyl}pyridines
Antimicrobial testing were carried out as described in Part-I Section-I(D). The
zones of inhibition of test solution are recorded in Graphical Chart No.4
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SYTHESIS AND BIOLOGICAL SCREENING OF 1-(4-CHLOROBENZOYL)-3 -(3,5-
DIBROMO-4-METHOXYPHENYL)-5-ARYL-4,5-DIHYDRO-1H-PYRAZOLES
Much interest have been focused around pyrazoline derivatives because of
their wide variety of pharmacological properties and industrial application. In view
of above findings and to achieve better drug potency, we have synthesized 1-(4-
chlorobenzoyl)-3-(3,5-dibromo-4-methoxyphenyl)-5-aryl-4,5-dihydro-1H-pyrazoles of
type-(V) by the condensation of  4-chlorobenzoyl hydrazine hydrate with chalcones
of type-(I).
The structure elucidation of synthesized compounds have been done on the
basis of elemental analyses, Infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
















Type(I) R = Aryl Type(V)
Studies on some comp. of med. interest
pyrazoline.....
75
Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2950 2975-2950 45
-CH3 C-H str.(sym.)    2837 2880-2860   “
C-H def.(asym.)    1467 1470-1435   “
C-H def.(sym.)    1379 1390-1370   “
Aromatic C-H str.    3045 3090-3030 46
C=C str.    1512 1540-1480   “
   1148 1125-1090   “
   1053 1070-1000   “
Ether C-O-C str.(sym)    1215 1275-1200 45
   1029 1075-1020   “
Halide C-Br str.     555 600-500   “
C-Cl str.     617 600-800   “
Carbonyl C=O str.    1656 1680-1652 46
Pyrazoline C=N str.    1569 1627-1580   “







































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.17-3.23 1H        double-doublet -CHa
      2. 3.82-3.90 1H        double-doublet -CHb
      3. 3.96 3H singlet Ar-OCH3
      4. 5.82 1H        double-doublet -CHc
      5. 7.74-8.82 10H multiplet Ar-H



































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(4-CHLOROBENZOYL)-3-
(3,5-DIBROMO-4-METHOXYPHENYL)-5-ARYL-4,5-DIHYDRO-1H-PYRAZOLES
(A) Synthesis of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-
1-ones
See Part-I, Section-I (C).
(B) Synthesis of 1-(4-Chlorobenzoyl)-3-(3,5-dibromo-4-methoxyphenyl)-5-
(4-chlorophenyl)-4,5-dihdro-1H-pyrazole
A mixture of (2E)-1-(3,5-dibromo-4-methoxyphenyl)-3-(4-chlorophenyl)-prop-
2-en-1-one. (4.39gm, 0.01 mol) in a 25 ml of glacial acetic acid and 4-chlorobenzoyl
hydrazine hydrate (1.58gm, 0.01 mol) was refluxed for 10 hrs. The resulting mixture
was poured on to crushed ice. The product was isolated and crystallized from
ethanol. Yield 72%, m.p. 1050C, Anal. Calcd. for C23H16Br2Cl2N2O2; Requires:
C, 47.38; H2.77; N, 4.80; Found: C, 47.45; H , 2.87; N, 4.75 %.
Similarly, other 1-(4-chlorobenzoyl)-3-(3,5-dibromo-4-methoxyphenyl)-5-aryl-
4,5-dihydro-1H-pyrazoles.
(C) Biological screening of 1-(4-Chlorobenzoyl)-3-(3,5-dibromo-4-methoxy
phenyl)-5-aryl-4,5-dihdro-1H-pyrazoles
Antimicrobial testing were carried out as described in Part-I Section-I(D). The
zones of inhibition of test solution are recorded in Graphical Chart No 5.
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Cyclohexenones are derivatives of cyclohexane with carbonyl group at 1-
position duoble bond at position-2(I). There are different types of cyclohexenone
derivatives but the groups attached to carbon atom exerted the greatest difference
in structure and properties.
SYNTHETIC ASPECT
Different methods for the preparation of cyclohexenone derivatives have been
described in literature1-14.
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(II) A review of the earlier literature by Gerald et al.16 describes representative
synthetic procedure of cyclohexenone derivative (III).
(III) Eman H. A. et al.17 have been prepared cyclohexenone derivative (IV) from
chalcone.
THERAPEUTIC IMPORTANCE
Cyclohexenones have various medicinal applications such as anthelmintic,
hypoglycemic, nematocidal, antibacterial, antifungal, antiviral, analgesic etc.
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Cyclohexenone possess cardiovascular, osteoporosis, menpausal symptoms,
estrogen dependent and cancers activities, which was reported by Jacobsen Poul
et al.19.
De Mesmaeker et al.20 prepared cyclohexenone carbonyl benzo thiophene
(I) as herbicides.
Eddington, et al.21 synthesised and evaluted anticonvulsant activity of Ethyl
4-[(substituted phenyl) amino ]-6-methyl-2-oxo-cyclohex-3-ene-1-carboxylates (II)
and their corresponding 5-methyl cyclohex-2-enone (III).
Cyclohexenone and its derivatives have been prepared and reported as
broad  spectrum of physiological properties viz. antibiotic22,23, bactericidal24,
herbicidal25, antimicrobial26, anticonvulsant27. Alekseeva L.M. and co-workers28
have synthesised cyclohexenone derivatives which are useful in neurotropic
activity. Toshiyuki et al.29 have prepared some novel cyclohexenones and screened
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Collis David J. et al.30 have documented cyclohexenone derivatives which
possess estrogenic activity. V. K. Ahluwalia et al.31 have reported some new
cyclohexenone as anti HIV-I, gastric secretion inhibitors and pesticidal activity.
Nagarajan and shenoy32 have prepared substituted cyclohexenones which shown
to possess marked antiinflammatory activity. Nagao et al.33 have reported
antiarhythmics activity of cyclohexenones. Inverse agonist for GABA activity34a of
some    derivatives have been investigated.
Antimicrobial activity have been studied by Salamu and Atshikh.34b
Cyclohexenone possess neutropeptide-γ-receptor antagonist activity which was
reported by Takehiro and co-workers35. Broughton Howard36 have demonstrated
cyclohexenone as GABA α5 receptor ligands for enhancing cognition properties.
Cyclohexenone possess inhibitory activity against the growth of lettuce seedling
found by kimura and co-workers37. Parekh and co-workers38 synthesised new
cyclohexenones as antimicrobial agents. Shklyaev Yu. et al.39 have prepared
cyclohexenones as potent biological agents. Cragoe et al.40 have synthesize some
cyclohexenone derivatives which was useful in the treatment of brain injury.
These valid observations prompted as to combine this nucleus into well known
pharmaceutical properties of 3,5-dibromo-4-methoxy acetophenone nucleus so as
to enhance the overall activities of resulting moiety, which have been described as
under.




SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL 4-(3,5-DIBROMO-4-
METHOXYPHENYL)-6-ARYL-2-OXOCYCLOHEX-3-ENE-1-CARBOXYLATES
Therapeutic importance of cyclohexenones aroused considerable interest to
synthesis ethyl 4-(3,5-dibromo-4-methoxyphenyl)-6-aryl-2-oxocyclohex-3-ene-1-
caboxylates of the type (VI)  by the cyclocondensation of (2E)-1-(3,5-dibromo-4-
methoxyphenyl)-3-aryl-prop-2-en-1-ones with ethylacetoacetate in the presence of
anhydrous K2CO3 in order to study their biodynamic behavior.
The structure elucidation of synthesized compounds have been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards. Aspergillus niger at a concentration of 40 µg/ml. The
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2927 2975-2950 86
-CH3 C-H str.(sym.)    2868 2880-2860   “
C-H def.(asym.)    1452 1470-1435   “
C-H def.(sym.)    1390 1390-1370   “
Aromatic C-H str.    3062 3090-3030 87
C=C str.    1531 1540-1480   “
   1095 1125-1090   “
   1066 1070-1000   “
Halide C-Br str.     555 600-500 86
Ether C-O-C str.(sym)    1263 1275-1200   “
   1066 1075-1020   “
Carbonyl C=O str.    1741 1735-1717 87
Cyclohex. C=O str.    1666 1685-1665   “























































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
     1. 1.21-1.25         3H triplet -CH2 -CH3
     2. 2.95         6H singlet -N-(CH3)2
     3. 3.90                     3H singlet Ar-OCH3
     4. 2.67         1H        double-doublet -Ha
     5. 2.83                     1H        double-doublet -Hb
     6. 4.02-4.10         2H quartet -CH2-
     7. 6.46         1H singlet -Hd
     8. 7.26         1H singlet -Hc
     9. 7.55         1H singlet -He














NMR SPECTRAL STUDIES OF ETHYL 4-(3,5-DIBROMO-4-METHOXYPHENYL)-6-(4-
N,N-DIMETHYLAMINOPHENYL)-2-OXOCYCLOHEX-3-ENE-1-CARBOXYLATE





























































































SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL 4-(3,5-DIBROMO-4-
METHOXYPHENYL)-6-ARYL-2-OXOCYCLOHEX-3-ENE-1-CARBOXYLATES
(A) Preparation of (2E) -1-(3,5- Dibromo-4-methoxy phenyl)-3-aryl-prop-2-
en-1-ones
See Part-I, Section-I (C).
(B) Preparation of Ethyl 4- (3,5-Dibromo-4-methoxyphenyl)-6-(4-N,N-
dimethylaminophenyl)-2-oxocylohex-3-ene-1-carboxylate
To a solut ion of (2E)-1-(3,5-dibromo-4-methoxy phenyl)-3-(4-N,N-
dimethylamino phenyl)-prop-2-en-1-one (4.39gm, 0.01 mol) in dry acetone,
anhydrous K2CO3 (5.42gm, 0.04 mol) and ethyl acetoacetate(2.60gm, 0.02 mol)
was added and the reaction mixture was stirred at room temperature overnight and
was filtered. The solvent from the filtrate on evaporation gave a solid, which was
crystallized from methanol. Yield 62%, m.p. 1200C, Anal.Calcd. for C24H25Br2NO4;
Requires: C, 52.29; H, 4.57; N, 2.54; Found : C, 52.36; H, 4.61; N, 2.50 %.
Simi lar ly,  o ther  Ethy l  4- (3,5-d ibromo-4-methoxyphenyl ) -6-ary l -2-
oxocyclohex-3-ene-1-carboxylates were prepared. The physical data and recorded
in Table No.6
(C) Biological screening of Ethyl-4-(3,5-dibromo-4-methoxyphenyl)-6-aryl-
2-oxocyclohex-3-ene-1-carboxylates
Antimicrobial testing were carried out as described in Part-I, Section (D).
The zones of inhibition of test solutions are recorded in Graphical Chart No.6
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Heterocyclic compounds bearing a 1,2-diazole ring system i.e. pyrazole ring
system, attached to benzene ring system are known as benzo pyrazoles or indazoles
(I). Buchner first described Indazole in 1869.
The compounds of medicinal interest in this group so far have been non-
steroidal antiinflammatory agents or analgesics.
SYNTHETIC ASPECT
Various method41-47 for the preparation of indazoles have been described
in the literature among the popular are
1. Indazoles can be synthesized by condensing48,49 hydrazine hydrate with
cyclohexenone derivatives.
2. Reaction of substituted azo sulfides with potassium-t-butoxide in DMSO lead
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3. Cyclocondensation of activated acetylene with hydrazine afforded indazole
derivatives51.
4. Indazoles52 can be prepared by the cyclization of 2,6-dialkoxy or hydroxyl
acetophenone hydrazones in presence of PPA.
5. Synthesis of some indazole derivatives53 by heating benzylidene aniline
derivatives in DMF was reported by Okhim L-Yu et al.
6. Indazole ring system54 can also be designed by the diazotization of
substituted anilines eg o-toludine.
7. Carbon Stephan and co-workers55 have described that the condensation of














































Indazole derivatives are biologically interesting class of compounds. They are















As reported earlier, indazoles are non-steroidal antiinflammatory agents or
analgesics, the prototype is benzydamine (I)71, a fairly potent nonsteroidal
antiinflammatory agent with significant antipyretic and analgesic properties.The other
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More over Yamaguchi Masahisa et al .74 prepared some indazole
derivatives as novel anti asthametic agents with dual activities of thromboxane A2
synthetase inhibitor and bronchodialations. Ooe Taknori et al.75 reported some
indazoles as hematinics, immuno stimulants and antitumor agents. Some indazole
derivatives76 showed activity for enhancing macrophage phagocytosis, improving
immunity and antitumor activity.
Lavielle Gilbert et al.77 documented the [(pyrrolidinyl) methyl]-indazoles(IV)
as 5-HT, like agonists and remedy for the treatment of migrains and schizoprenia78.
Mewshaw Richard Eric et al.79 have synthesized 4-amino ethoxy indazoles
useful as dopamine D2 agonists. Allan David and co-workers80 have synthesised
some indazole derivatives (V) and postulated them as fibrinogen antagonist.
Jain A.C. et al.81 have described the synthesis, separation of tautomers
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Thomas Lee and co-workers82 demonstrated the preparation and
formulation of 6-(imidazolinyl amino) indazoles (VII) as α-2 adreno-receptor
agonists.
Several co-workers have patented indazole derivat ives useful  as
hypolipidemic or hypocholersterolemic83 and cardiovascular84, agents Effland
Richard Charles et al.85 constructed 3-(pyridyl amino) indazoles and reported their
use as antidepressants and anxiolytics.
A wide variety of pharmacological properties have been encountered with
indazole systems. Keeping the above in mind some novel indazole derivative have
been synthesised which have been described as under.
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL 4-
(3,5-DIBROMO-4-METHOXYPHENYL)-6-ARYL-2-OXO-
CYCLOHEX-3-ENE-1-CARBOXYLATES



















SYNTHESIS AND BIOLOGICAL SCREENING OF  6-(3,5-DIBROMO-4-
METHOXYPHENYL)-4-ARYL-2,3a,4,5-TETRAHYDRO-2H-INDAZOL-3-ONES
The synthesis of indazole has attracted the attention of chemists because of
their  potent ia l  pharmcodynamic propert ies.  Looking to the interest ing
properties of indazoles, it appeared interest to synthesise a series of 6-(3,5-
dibromo-4-methoxyphenyl)-4-aryl-2,3a,4,5-tetrahydro-2H-indazol-3-ones of type
(VII) for  obtaining biologically potent agents, which were prepared by reacting ethyl
4-(3,5-dibromo-4-methoxyphenyl)-6-aryl-2-oxocyclochex-3-ene-1-carboxylates of
type (VI) with hydrazine hydrate in presence of glacial acetic acid.
The structure elucidation of synthesized compounds have been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards. Aspergillus niger at a concentration of 40 µg/ml.

















Type-(VI) R = Aryl Type- (VII)
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2925 2975-2950 86
-CH3 C-H str.(sym.)    2827 2880-2860   “
C-H def.(asym.)    1471 1470-1435   “
C-H def.(sym.)    1384 1390-1370   “
Aromatic C-H str.    3050 3090-3030 87
C=C str.    1490 1540-1480   “
   1091 1125-1090   “
   1064 1070-1000   “
Halide C-Br str.     530 600-500 86
Ether C-O-C str.(sym)    1261 1275-1200   “
Amide NH-(C=O)- str.    1662 1680-1636 87
Indazole C=N str.    1652 1645-1630   “
C=O str.    1652 1672-1652   “









































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
     1. 2.95         6H singlet -N-(CH3)2
     2. 3.95                     3H singlet Ar-OCH3
     3. 2.65         1H        double-doublet -Ha
     4. 2.85                     1H        double-doublet -Hb
     5. 6.96         1H singlet -Hd
     6. 7.35         1H singlet -Hc
     7. 7.14-7.67         7H multiplet Ar-H + He














NMR SPECTRAL STUDIES OF 6-(3,5-DIBROMO-4-METHOXYPHENYL)-4-(4-N,N-
DIMETHYLAMINOPHENYL)-2,3a,4,5-TETRAHYDRO-3H-INDAZOL-3-ONE



























































































SYNTHESIS AND BIOLOGICAL SCREENING OF  6-(3,5-DIBROMO-4-
METHOXYPHENYL)-4-ARYL-2,3a,4,5-TETRAHYDRO-2H-INDAZOL-3-ONES
(A) Preparation of (2E) -1-(3,5- Dibromo-4-methoxyphenyl)-3-prop-2-en-1-
ones
See Part-I, Section-I (C).
(B) Preparation of Ethyl 4-(3,5-dibromo-4-methoxyphenyl)-6-(4-N,N-
dimethylaminophenyl)-2-oxocyclohex-3-ene-1-carboxylate
See Part-III, Section-I(A).
(C) Preparation of 6- (3,5-Dibromo-4-methoxyphenyl)-4-(4-N,N-dimethyl
aminopheyl)-2,3a,4,5-tetrahydro-2H-indazol-3-one
A mixture of ethyl 4-(3,5-dibromo-4-methoxyphenyl)-6-(4-N,N-dimethylamino
phenyl)-2-oxocyclohex-3-ene-1-carboxylate (5.65gm, 0.01mol) in ethanol (20 ml),
hydrazine hydrate (0.5gm 0.01 mol) and acetic acid (2 ml) was refluxed at 80 0C for
4 hr on water bath. The residue obtained after cooling was  filtered and isolated and
crystal l ized from methanol.  Yield 58 %, m. p.  148 0C. Anal.  Calcd. for
C22H21Br2N3O2       Requires C, 50.89; H, 4.08; N, 8.09% Found C, 50.95; H,
4.12; N,  8.01%.
Similarly other, 6- (3,5-dibromo-4-methoxyphenyl)-4-aryl-2,3a,4,5-tetrahydro-
2H-indazol-3-ones were prepared. The physical data were recorded in Table No. 7.
(C) Biological screening of 6- (3,5-Dibromo-4-methoxyphenyl)-4-aryl-
2,3a,4,5-tetrahydro-2H-indazol-3-ones
Antimicrobial testing were carried out as described in Part-I, Section (D). The
zones of inhibition of test solutions are recorded in Graphical Chart No.7
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INTRODUCTION
Pyridines are of considerable chemical and biological importance, as the
pyridine derivatives have displayed diverse pharmacological activities1 The simple
pyridine compounds are synthesised by the cyclisation of aliphatic raw materials,
while various polysubstituted pyridine compounds prepared from acyclic compounds
in a manner similar to chemistry of the benzenoid chemistry.
SYNTHETIC ASPECT
A variety of methods are available for the preparation of 3-cyano pyridines in
literature 2-8. Some of them are as follows.
1. A. Sakuri and Midorikawa have reported that malononitrile reacts with α,β-
unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted
pyridines9,10
2. Samour and co-workers11,12  prepared  substituted cyano pyridines by  the
condensation of chalcones with ethyl acetoacetate and malononitrile in
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3. Cyano pyridine derivatives (I) are obtained by the reaction of R-CO-CH3 with
2-cyanothioacetamid in presence of N-methyl morpholine, which have been
prepared by Dayachenko V.D.13 Cyano pyridine derivatives (II) have also
reported by Metwalla Nadia et al.14
4. Substituted cyanopyridine derivatives were also prepared from 3-substituted
phenyl pyrazolone derivatives with malononitrile.15
5. G. Ege and co-workers and H. Kurithara et al. have prepared 2-amino
3-cyano pyridine derivatives by using arylidene, malononitrile,
lithiumisopropylamide and DMF dichloride.16,17
6. J. M. Babbit et al.18 synthesized 3-cyano pyridines by the cyclo condensation
of cyano acetamide with ethyl acetoacetate in presence of alkali.
7. Quiroya Jairo and co-workers19  have synthesized pyrido-[2,3-d]-pyrimidine-
4-[3 H]-ones (III) from 6-amino-2-pyrimidinones and arylidene malononitrile.
8. Aromatic nitrile can be prepared from the corresponding primary carboxylic
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REACTION MECHANISM
The reaction proceeds through conjucated addition of active methylene
compounds to the α,β-unsaturated system as shown below.
THERAPEUTIC IMPORTANCE
Cyanopyridine derivatives have been found to posses wide range of
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Harda,  H i rok i ;  e t  a l .33  have prepared 2-acy lamino-3,5-
dicyanopyridine derivatives as high conductance type calicium sensitivity K channel
openings drugs. (I),(II).
Villhauer, et al.34 synthesised cyano pyridine as antihyper glycemic
agent are. Timothy B. et al.35 prepared hydroxy aryl pyridines (III)(IV), which used for
asthama and ischemia, in addition to compounds are show antitumor and immuno
suppressant activity.
Resentreter et al.36 prepared 2-thio-3,5-dicyano-4-phenyl-6-amino pyridines
(V) as adenosine Al receptor agoinsts in the treatment of cardiacorurogential
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El-Nabawia and co-workers 37 have prepared cyano pyridine and studied their
antimicrobial activity, Parekh el al.38,39 have synthesised the series of cyano pyridies
and reported their antimicrobial activities.
Hammama Abou and co-workers 40 synthesised 3-cyano pyridine derivatives
(VI) and reported as anticancer and anti HIV agents.
More ever, Grant N and co-workers41 synthesized some cyano pyridines (VII)
and reported as a antibacterial agents. Abd EL-Galil and E-Amr42 prepared
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Mann Padele and co-workers43 have reported some 3-cyano pyridines as
anti inflammatory agents. Villalobas Anabella et al.44 have prepared some new 3-
cyano pyridines and reported them as choline-steurase inhibitors.
 Bhatt and co-workers45 have synthesised 3-cyano pyridines and postulated
them as inmuno suppressive agents. Prancis and coworkers46 have studied the
effect of some substituted pyridines on the growth of the walker carcino
sarcome-256 in tissue culture.
The insecticidal47-48 fungicidal49 and other pesticidal activities50 have
documented in the literature by several workers.
Furthermore cycnopyridines are also found applicable in the dyeing of
polyester and acrylic fiber51,52. The oxidie activator bleaching activity of cyano
pyridine has been proved by Rees Wayne M.53
Moreover Oshidu murio54 have constructed some new cyano pyridine
derivatives which inhibitertceberal edema and delayed neuron death. Hence they
are useful as caberal eduma inhibitor or cerebrovascular disorder remedies.
Thus, diverse biological activities have been encountered in compounds
containing cyano pyridine ring system. Therefore  it was considered worth while to
synthesise cyano pyridine derivatives which have been described as under.
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-3-CYANO-6-(3,5-
DIBROMO-4-METHOXYPHENYL)-4-ARYL-PYRIDINES
Cyanopyridines play a vital role owing to their range of biological and
physiological activites. In the light of these biological activities and variety of
indust r ia l  app l ica t ions,  some new 2-amino-3-cyano-6- (3 ,5-d ibromo-4-
methoxyphenyl)-4-aryl-pyridine derivatives of type (VIII) have been prepared, by the
condensation of (2E)-1-(3,5-dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-1-ones of
type (I) with malononitrile in presence of ammonium acetate.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass Spectrometry.
All the compounds have been evaluated for their invitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards. Aspergillus niger at a concentration of 40 µg/ml. The
















Type = (VIII)R = ArylType - (I)
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2927 2975-2950 55
-CH3 C-H str.(sym.)    2858 2880-2860   “
C-H def.(asym.)    1471 1470-1435   “
C-H def.(sym.)    1352 1390-1370   “
Aromatic C-H str.    3060 3090-3030 56
C=C str.    1533 1540-1480   “
   1129 1125-1090   “
Halide C-Br str.     545 600-500 55
Ether C-O-C str.(sym)    1263 1275-1200   “
Pyridine C=C str.    1622 1650-1520 56
C=N str.    1571 1580-1550   “
Nitrile C=N str.    2212 2240-2120   “
Amine N-H str.    3361 3380-3350   “










































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.96 3H singlet Ar-OCH3
      2. 3.98 3H singlet Ar-OCH3
      3. 5.27 2H singlet -NH2
      4. 6.97 1H singlet -Ha










NMR SPECTRAL STUDIES OF 2-AMINO-3-CYAN0-6-(3,5-DIBROMO-4-
METHOXYPHENYL)-4-(4-METHOXYPHENYL)-PYRIDINE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL OF 2-AMINO-3-CYANO-6-(3,5-DIBROMO-4-
METHOXYPHENYL)-4-ARYL-PYRIDINES.
(A) Synthesis of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-1-
ones.
See Part-I, Section-I (C).
(B) Synthesis of 2-Amino-3-cyano-6-(3,5-dibromo-4-methoxyphenyl)-4-
chlorophenyl-pyridines
A mixture of (2E)-1-(3,5-dibromo-4-methoxyphenyl)-3-(4-chlorophenyl)-prop-
2-en-1-one (4.3 gm, 0.01 mol), malononitrile (0.60gm, 0.01 mol) and ammonium ac-
etate (6.6gm, 0.08 mol) dissolved in ethanol (20ml), the content was heated
under reflux for 12 hrs. The product was isolated and crystallized from ethanol. Yield
70%, m. p. 170 0C,  Anal. Calcd. for C19H12 Br2ClN3O; Requires: C,46.23;  H,2.45;
N,8.18; Found: C,46.28 ; H,2;55; N,8.14 %.
Similarly, other 2-Amino-3-cyano-6-(3,5-dibromo-4-methoxyphenyl)-4-aryl-
pyridines
(C) Biological screening of 2-Amino-3-cyano-6-(3,5-dibromo-4-methoxy
phenyl)-4-aryl-pyridines
Antimicrobial testing were carried out as described in Part-I Section-1 (D).
The zones of inhabition of test solution are recorded in Graphical Chart No 8.
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INTRODUCTION
Pyran derivatives constitute a class of interesting compounds finding
versatile applications in various fields viz. pharmaceuticals, dyes, agrochemicals
and sweet smelling substances. They are also present in some natural products like
vitamin E, cloves, certain alkaloids and some natural coloured compounds.
Pyrans are six membered doubly unsaturated compounds containing one
oxygen atom in the ring. The two double bonds may be conjugated or isolated known
as α or 1,2-pyran and γ or 1,4- pyran respectively.
     α or 1,2-pyran         γ or 1,4-pyran
A high degree of stabilization of the pyran nucleus is achieved by substituting
phenyl group in the 2 and 4-preferably and also in the 6-position.
SYNTHETIC ASPECT
Different methods are available in literature 1-10 for the preparation of pyran
derivatives.
The popular methods are
1. Reaction between α, β- unsaturated carbonyl system with (CH2CN)2 led to
corresponding 2-amino-3-cyano-4H-pyrans11
O O
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2.  Fabrizi et al.12 have reported the synthesis of dihydro pyrans via pd-catalysed
cyclisation of 2-alkyl-1,3-dicarbonyl compounds and vinylic triflates or halides.
3. Some alkylidene 2-H-pyrans were synthesized13 by thermal electrolyting ring
closure of divinyl alkenyl.
4. Reaction of cyclohexenone with cinnamonitriles, gave substituted pyran
derivatives14.
5. N. M. Abed and co-workers15 have synthesized pyran derivatives, exist in
equilibrium with (II) in solution.
6. Abdel Ghany H. et al.16 have prepared some new pyran derivatives by
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MECHANISM
The reaction mechanism for the formation of pyran derivative proceeds through
Michael addition of an active methylene of malononitrile to the β- carbon atom of
chalcone.
THERAPEUTIC IMPORTANCE
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10. CNS active agent27
11. Antipyretic28
El Gaby Mohamed S. and co-workers29 described the synthesis and
anticancer activity of pyran containing fluorine (I) and (II), to enhance the anticancer
and anti HIV activity.
Elassar A.Z. et al.30 have prepared some new cyanopyran derivatives (III)
exhibiting in vitro antifungal and antibacterial activity.
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More ever, sonker R. M.32 have synthesized some new 2-amino-3-cyano
pyran derivatives, possessing antibacterial and antifungal activity containing
coumarin heterocycles. Fathy F. Alddet hatif et al.33 and Piao-minz-zhu et al.34 have
reported the synthesis of pyran derivatives and studied their biological activity.
Tomich faul et al.35 have also reported the anti HIV activity of some pyran
derivativeds.Antitumor activity of some pyran derivative was reported by Nobble
stuart A.36 Long teans37 have prepared some cyano pyran derivative as gastric
acid secretion inhibitors. Adrinolytic activity was described by kossakowshi zery
et al.38
Further more, some of the pyran derivatives have been patented for their use
as inh ib i tors  of  ce l l  pro l i ferat ion39,  ant i  hyper tens ive40,  ant i tumor41,
antagonists42, 43 and antiviral44 agents.
These observations prompted us to combine this nucleus into 4-methoxy-3,5-
dibromo acetophenone so as to enhance the overall activities of resulting moiety,
which have been described as under
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-AMINO-3-CYANO-6-(3,5-
DIBROMO-4-METHOXYPHENYL)-4-ARYL-PYRANS
Cyano pyran derivatives have been found to be associated with various
pharmacological activities. These findings encouraged us to synthesise, some novel
2-amino-3-cyano-6-(3,5-dibromo-4-methoxyphenyl)-4-aryl-pyrans derivatives of
type (IX) by the cyclocondensation of (2E)-1-(3,5- dibromo-4-methoxyphenyl)-3-aryl-
prop-2-en-1-ones of type-(I), with malononitrile in pyridine.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and farther supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The















 Type (I) Type (IX)R = Aryl
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2930 2975-2950 44
-CH3 C-H str.(sym.)    2858 2880-2860   “
C-H def.(asym.)    1440 1470-1435   “
C-H def.(sym.)    1360 1390-1370   “
Aromatic C-H str.    3060 3090-3030 45
C=C str.    1477 1540-1480   “
   1155 1125-1090   “
Halide C-Br str.     550 600-500 44
Ether C-O-C str.(sym)    1238 1275-1200   “
Pyran C=C str.    1614 1650-1520 45
Nitrile C=N str.    2214 2240-2120   “
Amine N-H str.    3382 3380-3350   “


































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.95 3H singlet Ar-OCH3
      2. 5.42 2H singlet -NH2
      3. 6.75-6.78 1H doublet -Hb
      4. 7.25-7.28 1H doublet -Ha









NMR SPECRAL STUDIES OF 2-AMINO-3-CYANO-6-(3,5-DIBROMO-4-
METHOXYPHENYL)-4-(4-CHOROPHENYL)-PYRAN
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 EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREINING OF 2-AMINO-3- C YA N O - 6 - ( 3 , 5 -
DIBROMO-4-METHOXYPHENYL)-4-ARYL-PYRANS
(A) Synthesis of (2E)-1-(3,5-dibromo-4-methoxy phenyl)-3-aryl-prop-2-en-1-
ones
See part-I, Section-I(C).
(B) Synthesis of 2-Amino-3-cyano-6-(3,5-dibromo-4-methoxyphenyl)-4-(4-
chorophenyl)-pyran
A mixture of (2E)-1-(3,5-dibromo-4-methoxyphenyl)-3-(4-chlorophenyl)-prop -
2-en-1-one (4.30gm, 0.01 mol) and malononitrile (0.66gm, 0.01 mol) dissolved in
pyridine (20 ml) was heated under reflux for 10 hrs. on oilbath. The reaction mixture
was cooled and poured on to crushed ice. The residue was neutralized with 20%
HCl, where upon a solid separated out, which was filtered and crystallized from
ethanol. Yield 70%, m.p.130 oC  Anal. Calcd. for C19H13Br2ClN2O2;  Requires:
C,45.96; H, 2.64; N, 5.64 %; Found: C, 45.98; H,2.71; N, 5.58%.
Similarly, other 2-amino-3-cyano-6-(3,5-dibromo-4-methoxyphenyl)-4-aryl-
pyrans were prepared. The physical data and recorded in Table No.9
(C)  Biological screening of 2-Amino-3-cyano-6-(3,5-dibromo-4-methoxy
 phenyl)-4-aryl-pyrans
Antimicrobial testing were carried out as described in Part-I, Section-I(D).
The zones of inhibition or test solution are recorded in Graphical Chart No.9
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INTRODUCTION
2-Amino pyrimidine is the most important member of all the diazines, as the
ring system occurs widely in living organisms. Gabriel and colman first isolated
pyrimidine in 1899. 2-Amino pyrimidine and its derivatives represent one of the most
active classes of compounds possessing a wide spectrum of biological activities.
SYNTHETIC ASPECT
Synthesis of 2-amino pyrimidines have been described in literature1-3 some
of them are as under.
1. Abd-El-Galil E. Amr4 synthesised amino pyrimidine by the reaction of
chalcone with guanidine hydrochloride in presence of sodium hydroxide.
2. Rasaki Abayomi Osisany5 synthesised 2-amino pyrimidines by the reaction
of chalcone epoxide with guanidine carbonate in xylene.
3. B. K. Karale et al.6 have prepared 2-amino pyrimidines from schiff bases of
3-formyl chromones.
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REACTION MECHENISM
The following mechanism seems to be operable for the condensation of
chalcones with guanidine hydrochloride in presence of alkali.
THERAPEUTIC IMPORTANCE









Moreover Devi. F. Sree and co-workers21 have synthesised, pyrimidine
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Zimmermann Juerg22 synthesised some amino pyrimidine derivatives and
reported their use in  therapy of tumoral diseases. Boschelli Diane harries
et al.23 have documented some amino pyrimidine derivatives (II) as inhibitor of
cellular proliferation.
Chaudhari and co-workers24 have prepared N-6-(2-amino pyrimidin-4-yl)-
quinoline-4,6-diamines. (III) as N-type calcium channel antagonists for treatment of
pain.
Patil L. R. and co-workers25 synthesised some new pyrimidines bearing
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Robson, clative et al.26 have prepared amino pyrimidine derivatives (V) as
novel fluorescent, antifolate agent, pap and MRP-over expressing tumor cell lines.
Henrie, Robert N. and co-workers27 have synthesised amino pyrimidines,
useful as active ingredients in insecticidal and acaricidal compounds, Hisaki
Masakatsu and co-workers28 have prepared some amino pyrimidines as antirota
viral agent, useful for the prophylaxis and in infant diarrhea. Jean-Paul et al.29 have
reported some amino pyrimidine derivatives as dopamine D4 - antagonists.
As described earlier, so many drug constitute an amino pyrimidine ring
system, some well known drugs are Minoxidil30 (VI) is an effective hypotensive agent,
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Further more, Shir P. Shingh et al.32 have reported the antimicrobial activity
of 4-(4-pyrazoly)-2-aminopyrimidine derivatives (VIII). Kothari Seema33 have
synthesised some amino pyrimidines and tested their antibacterial and herbicidal
activity.
Amino pyrimidine derivatives show varied biological and pharmacological
properties. Therefore, in view of this interesting finding, the synthesis of 2-amino
pyrimidine has been under taken as described as under.


















  (VI)     (VII)       (VIII)
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SECTION I
SYNTHESIS AND BIOLOGICAL SCREENING OF 4- (3 ,5-DIBROMO-4-
METHOXYPHENYL)-6-ARYL-PYRIMIDINE-2-AMINES
Compounds containing pyrimidine ring are widely distributed in nature. Many
amino pyrimidine derivatives are reported to possess different biological activities.
In view of these report; it was considered, worthwhile to synthesize some new 4-
(3,5-dibromo-4-methoxyphenyl)-6-aryl-pyrimidine-2-amines of type- (X) to study their
biological activities. Amino pyrimidine derivatives have been prepared by the
reaction of the chalcones of type- (I) with guanidine hydrochloride in presence of
potassium tertiary-butoxide in tertiary-butanol shown as under.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards, Aspergillus niger at a concentration of 40 µg/ml. The





















Type (I)   R = Aryl   ` Type (X)
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2927 2975-2950 34
-CH3 C-H str.(sym.)    2852 2880-2860   “
C-H def.(asym.)    1469 1470-1435   “
C-H def.(sym.)    1386 1390-1370  “
Aromatic C-H str.    3122 3090-3030 35
C=C str.    1529 1540-1480   “
   1147 1125-1090   “
Ether C-O-C str.(sym)    1261 1275-1200 34
Amine NH2- str.    3375 3559-3350   “
Pyrimidine C=N str.    1575 1580-1520 35
Halide C-Br str.    596 600-500   “
C-Cl str.    740 600-800   “





































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.96 3H singlet Ar-OCH3
      2. 7.14 1H singlet -Ha
      3. 7.22-7.52 7H multiplet Ar-H







NMR SPECTRAL STUDIES OF 4-(3,5-DIBROMO-4-METHOXYPHENYL)-6-
PHENYL-PYRIMIDINE-2-AMINE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 4- (3 ,5-DIBROMO-4-
METHOXYPHENYL)-6-ARYL-PIRIMIDINE-2-AMINES
(A) Synthesis of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-
1-ones
See part-I, Section -1(C).
(B) Synthesis of 4-(3,5-Dibromo-4-methoxy phenyl)-6-(4-chlorophenyl)-
pyrimidine-2-amine
A mixture of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-(4-chlorophenyl)-
pyrimidine-2-amine (4.3 gm 0.01 mol) and guanidine hydrochloride (1.10gm, 0.01
mol) was refluxed in potassium-t-butoxide (11.2gm, 0.01 mol) in t-butanol (20ml) on
a water bath for 4-5 hours. The solvent was evaporated and the residue was
neutralized with 20% HCl, the separated solid was filtered out and crystallized from
ethanol. Yield 62%, m.p. 1560C, Anal. Calcd. for C17H12Br2ClN3O;  C, 43.48;
H, 2.58; N, 8.95; Found: C, 43.55; H, 2.50; N, 8.89 %.
Similarly, other 4-(3,5-dibromo-4-methoxyphenyl)-6-aryl-pyrimidine-2-amines
were prepared. The physical data are recorded in Table No.10
(C) Biological screening of 4-(3,5-dibromo-4-methoxyphenyl)-6-aryl-
pyrimidine-2-amines
Antimicrobial testing were carried out as described in Part-I Section-1 (D).
The zones of inhibition of test solution are recorded in Graphical Chart No.10
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INTRODUCTION
Piperidinones are well known for their antibacterial and antiinflammatory
properties. It plays an important role as intermediate in the synthesis of drug.
It enhances the biological activity, when attached with other compounds.
SYNTHETIC ASPECT
Different methods have been documented for the synthesis of piperidinones
in litrature1-14
1. B. shrivakumar et al.15 have synthesized cyano piperidones by reaction of
chalcones with cyano acetamide in presence of sodium ethoxide.
2. Hamed, A. A. et al.16 have synthesised piperidones by reaction of
chalcones with cyano acetamide in presence of sodium ethoxide
3. Nelson, Richard V. et al.17 have prepared piperidones by reaction of
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THERAPEUTIC IMPORTNACE
Piperidinoes are reported to exhibit a wide varieties of theraputic activities
such as
1. ACE and NEP  activity18
2. Anesthetic19









Kobuyashi  e t  a l .31  have synthesised  p iper id inones ( I )  as drug
intermediate for biological active compounds.
Chabert, Nathalic et al.32 have synthesised 2-piperidino alkyl-2-piperidinones
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Maccoss, Malcom et al.33 have prepared pipridinones (III) as modulators of
chemokine receptor activity
More over, Timothy, J. et al.34 reported 2-piperidinones as analogous fashion
by employing (DHQD)2 AQN in the intial Ad reactivity Micovic. Ivan U. et al.35
synthesised 2-piperidinones and reported their analgesic activity. Robl, Jeffrey et
al.36 reported 2-piperidinones as hemarable inhibitor of ACE and NEP activity. Laker,
Tim., et al.37 sytnhesized 2-piperidinone derivatives and their biological activity.
With an intention of preparing the compounds possesing better therapeutic
activity, we have undertaken the synthesis of cyanopiperidinones bearing 3,5-
dibromo-4-methoxy acetophenone moity which have been discribed under.
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF 3-CYANO-4-(3,5-DIBROMO-4-
METHOXYPHENYL)-6-ARYL-2-OXOPIPERIDINES
          Piperidinones have been reported to have various pharmacological activities
like anticancer, anticonvulsant etc. In order to achieving better drug potency, we have
prepared piperidinone derivatives of type -(XI) by the cyclo condensation of (2E)-1-
(3,5-d ibromo-4-methoxyphenyl ) -3-ary l -prop-2-en-1-ones of  type( I )  wi th
cyanoacetamide in presence of sodium ethoxide in ethanol.
  The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear megnatic resonance
spectroscopy and further supported by Mass spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards from positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2923 2975-2950 38
-CH3 C-H str.(sym.)    2854 2880-2860   “
C-H def.(asym.)    1460 1470-1435   “
C-H def.(sym.)    1380 1390-1370   “
Aromatic C-H str.    3076 3090-3030 39
C=C str.    1566 1540-1480  “
   1085 1125-1090  “
Halide C-Br str.    557 600-500 38
Ether C-O-C str.(sym)    1199 1275-1200
Piperidinone C=N str.    2218 2240-2120 39
C=O str.    1651 1760-1655  “
N-H str.    3425 3450-3250  “
N-H def.    1566 1650-1580  “












































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.95 3H singlet           Ar-OCH3
      2. 4.2 2H triplet -Ha,Hb
      3. 5.65 2H dublet -Hc













NMR SPECTRAL STUDIES OF 3-CYANO-4-(3,5-DIBROMO-4-METHOXYPHENYL)
-6-(4-CHLOROPHENYL)-2-OXO-1,2-DIHYDROPYRIDINE
Piperidinones.....
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 3-CYANO-4-(3,5-DIBROMO-4-
METHOXY PHENYL)-6-ARYL-2-OXOPIPERIDINES
(A) Synthesis of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-
1-ones
 See Part-I, Section-I (C).
(B) Synthesis of 3-Cyano-4-(3,5-dibromo-4-methoxyphenyl)-6-phenyl-2-
oxopiperidine
 (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-phenyl-1-prop-2-en-1-one (3.96gm,
0.01 mol) in (25ml) ethanol and sodium salt of cyano acetamide (1.0gm, 0.012 mol)
was refluxed for 8 hrs. on a waterbath. The reaction mixture was concentrated and
poured in to cold dil. HCl. The product was isolated and crystalised from methanol
Yield 60%; m.p. 278 oC ; Anal. Calcd. for C19H16Br2N2O2 Requires:C,49.17;
H,3.47; N, 6.04%  Found: C,49.25; H,3.55; N, 5.99 %.
Similarly, other 3-Cyano-4-(3,5-dibromo-4-methoxyphenyl)-6-aryl-2-
oxopiperidines were prepared. The physical data are recorded in Table No.11
(C) Biological screening of 3-Cyano-4-(3,5-dibromo-4-methoxyphenyl)-6-
aryl-2-oxopiperidines
Antimicrobial testing were carried out as described in Part-I Section-1(D).
The zones of inhibition of test solutions are recorded in Graphical Chart No.11
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INTORDUCTION
     Pyridones, which belong to important group of heterocylic compound have been
extensively explore for their applications in the field of medicine. Pyridine with a
carbonyl group at position-2 (I) have been subjected of extensive study in recent
past. Numerous reports have appeared in the literature, which highlight, their
chemistry and use.
2-Pyridones are derivatives of pyrimidine with carbonyl group at 2-position
(I) Some 2-pyridones are physiologically as well as pharmacologically important which
are as under: eg. Amrinone (II), Ciclopirox (III) and Menthylprylon (IV).
Synthetic pyridone derivatives contribute much to the searchable literature of
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SYNTHETIC ASPECT
Different methods for the preparation of 2-pyridones are as follows
1. K. Folkers and S. A. Harris1  have synthesised 3-cyano-2-pyridone by the
condensation of cyanoacetamide with 1,3-diketone or 3-ketoester.
2. G. Simchen and G.Enremmann2 have synthesised 2-pyridone in which the
ring nitrogen comes from a nitrile group in a cyclic precursor.
3. M. A. Sluyter and co-worker3 have prepared fused 2-pyridones.
THERAPEUTIC IMPORTANCE
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Abou EL Fotooh and co-worker14 have demonstrated pyridones (VI) as
anticancer agent. E. Amer15 prepared 3-cyano 2-pyridone derivatives (VII)
displaying high antimicrobial activity.
Mukhtar Hussain Khan and co-worker16,17 have prepared 2-pyridone































Morishita koji et al.13 have synthesised m-(2-oxo-1,2-dihydropyridyl)
derivatives (V) possessing cholesterol acyltransterase (ACAT) inhibitory activity and
are useful for the treatment of hyperlipidemia and arteriosclerosis.
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H. Posnes18 synthesised 2-pyridones and 2-pyrones as physiologically
active compounds. Peter and co-workers19 have prepared pyridinylmethyl
substituted pyridines and tested as angiotesin II antagonists. Collins et al.20
prepared heteroaryl pyridones as GABA α2/α3 ligands (X). Pednekar21 synthesised
fused 2-pyridone derivatives (XI),(XII) and (XIII) as useful heterocyclic moieties as
they possess a broad spectrum of biological activity such as antiviral, CNS
depressant, bactericidal and ulcer inhibitor.
M. G. Nizamuddin et al.22 have prepared cyano pyridone derivatives (XIV)
and documented their antifungal activity.
Davi. F. Sree ; et al.23 have prepared cyano pyridone derivative (XIV) and
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Azama yutaka et al.24 and Devadas et al.25 have prepared cyano pyridone
derivative for medicinally important compounds.
Moreover  several co-workers have prepared 2-pyridones as S3 site of throbin
inhibitor26, herbicidal27, SH2 domain inhibitor28, antimicrobial29, GABA-α
receptor30 and antiinflammatory31activity.
Upadhyay and co-worker32  have synthesised cyano pyridone derivatives
which showed antifungal and antileishmanial activeties.
Looking to the interesting properties of pyridones, we have synthesised some
new pyridone derivatives, which have been described as under
SECTION - I : SYNTHESIS AND BIOLOGICAL SCREENING OF 3-CYANO-
4-(3,5-DIBROMO-4-METHOXYPHENYL)-6-ARYL-2-OXO-1,2-
DIHYDROPYRIDINES
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF 3-CYANO-4-(3,5-DIBROMO-4-
METHOXYPHENYL)-6-ARYL-2-OXO-1,2-DIHYDROPYRIDINES
In view of powerful biological activities shown by cyano pyridones, like
antimicrobial and antitubercular, it was worthwhile to synthesized some novel cyano
pyridone derivatives possessing better biological activity. Synthesis of some new 3-
cyano-4-(3,5-dibromo-4-methoxyphenyl)-6-aryl-2-oxo-1,2-dihydropyridines of
type(XII) carried out by condensation of chalcones of type(I) with ethylcyanoacetate
in presence of ammonium acetate as under.
The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and farther supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards gram positive and gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The















Type (I)        
         
  
Type (XII)R = Aryl
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2956 2975-2950 33
-CH3 C-H str.(sym.)    2858 2880-2860   “
C-H def.(asym.)    1444 1470-1435   “
C-H def.(sym.)    1351 1390-1370   “
Aromatic C-H str.    3060 3090-3030 34
C=C str.    1548 1540-1480   “
   1155 1125-1090   “
Halide C-Br str.    540 600-500 33
Ether C-O-C str.(sym)    1238 1275-1200   “
Pyridone          C=N str.    2214 2240-2120 34
C=O str.    1734 1760-1655   “
N-H str.    3382 3450-3250   “
N-H def.    1641 1650-1580   “


































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.94 3H singlet Ar-OCH3
      2. 6.59 1H singlet -Ha
      3. 7.43-7.60 6H multiplet -Ar-H









NMR SPECTRAL STUDIES OF 3-CYANO-4-(3,5-DIBROMO-4-METHOXYPHENYL)-6-
(4-CHLOROPHENYL)-2-OXO-1,2-DIHYDROPYRIDINE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF  3-CYANO-4-(3,5-DIBROMO-
4-METHOXY PHENYL)-6-ARYL-2-OXO-1,2-DIHYDROPYRIDINES
(A) Synthesis of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-aryl-prop-2-en-
1-ones
See Part-I, Section-I (C).
(B) Synthesis of 3-Cyano-4-(3,5-dibromo-4-methoxy phenyl)-6-(4-chloro-
phenyl)-2-oxo-1,2-dihydropyridine
A mixture of (2E)-1-(3,5-dibromo-4-methoxyphenyl)-3-(4-chlorophenyl)-prop-
2-en-1-one. (4.39gm, 0.01 mol), etylcyanoacetate (1.13gm, 0.01 mol) and
ammonium acetate (5.92gm, 0.08mol) was refluxed for 8 hrs. The resulting mixture
was poured on to crushed ice. The product was isolated and crystallized from
ethanol. Yield 68%, m.p. 3000C, Anal. Calcd. for C19 H11Br2ClN2O2; Requires:
C, 46.14; H, 2.24; N, 5.66; Found: C, 46.20; H , 2.28; N, 5.60%.
Similarly, other 3-cyano-4-(3,5-dibromo-4-methoxy phenyl)-6-aryl-2-oxo-1,2-
dihydropyridines.
(C) Biological screening of 3-cyano-4-(3,5-Dibromo-4-methoxy phenyl)-6-
aryl-2-oxo-1,2-dihydropyridine
Antimicrobial testing were carried out as described in Part-I Section-I(D). The
zones of inhibition of test solution are recorded in Graphical Chart No 12.
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2-Pyranone is a six membered oxygen containing heterocyclic compound
having keto group at 2-position. It was discovered form 2-hydroxy succinic acid
through Von pechmann synthesis. Then after the chemistry of 2-pyranones has
aroused a great interest due to its medicinal interest.
     Biological importance of pyranone derivatives is well known. They have been
reported to be active as an anticoagulants, HIV protease, serine proteases,
herbicides, antialeish manid, anticancer, insecticidal, antibiotic etc.
SYNTHETIC ASPECT
Different methods have been documented for the synthesis of pyranones in
literature1-23.








The probable reaction mechanism can be explaining on the basis of Pechmann










9. Induced liver injury in rats33





































Studies on some comp. of med. interest
Pyranone.....
186
Rehse,  K laus et  a l .35 prepared and evaluted 2-pyranone ( I I )  as
anticoagulants and their N-oxidase.
Groutas, william C. et al.36 have prepared some 2-pyranone(III) derivatives
and reported them as inhibitors of the serine proteases.
C2-symmmetry based resin of bis-sulfonamide dihydropyrones (IV) is a
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These valid observations prompted us to combine this nucleus with 4-methoxy-
3,5-dibromo acetophenone so as to enhance the overall activities of resulting
moiety, which have been described as under:


















SYNTHESIS AND BIOLOGICAL SCREENING OF 6-(3,5-DIBROMO-4-METHOXY
PHENYL)-4-ARYL-3,4-DIHYDRO-2H-PYRAN-2-ONE
          Pyranones have been reported to have various pharmacological activities like
anticancer, antibacterial etc. In order to achieving better drug potency, we have
prepared pyranone derivatives of type -(XIII) by the cyclo condensation of (2E)-1-
(3,5-dibromo-4-methoxy phenyl)-3-aryl-prop-2-en-1-ones of type-(I) with  ethylphenyl
acetate in presence of sodium ethoxide in benzene
 The structure elucidation of synthesized compounds has been done on the
basis of elemental analyses, infrared and 1H Nuclear magnetic resonance
spectroscopy and further supported by Mass spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
anti bacterial activity towards gram position and gram negative Aspergillus niger.
At a concentration of 40 µg/ml. The biological activities of synthesized compounds
















Type  (I) R = Aryl Type (XIII)
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Type Vibration            Frequency in cm-1 Ref.
Mode Observed Reported
Alkane C-H str.(asym.)    2925 2975-2950 38
-CH3 C-H str.(sym.)    2854 2880-2860   “
C-H def.(asym.)    1454 1470-1435   “
C-H def.(sym.)    1389 1390-1370   “
Aromatic C-H str.    3060 3090-3030 39
C=C str.    1544 1540-1480   “
   1091 1125-1090   “
Halide C-Br str.    538 600-500 38
Ether C-O-C str.(sym)    1210 1275-1200   “
Pyranone C=O str.    1706 1740-1700 39


































Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency range:
4000-400 cm-1 (KBr disc.)
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Internal standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer
(300 MHz)
   Signal Signal Position   Relative No.        Multiplicity          Inference
     No.      (δ ppm)     of Proton
      1. 3.95 3H singlet Ar-OCH3
      2. 5.65 1H triplet -Hb
      3. 5.35 1H doublet -Hc
      4. 7.00-8.14 12H multiplet Ar-H
      5. 8.15 1H doublet -Ha
















































































SYNTHESIS AND BIOLOGICAL SCREENING OF 6- (3 ,5-DIBROMO-4-
METHOXYPHENYL)-4-ARYL-3-PHENYL- 3,4-DIHYDRO-2H-PYRAN-2-ONES
(A) Synthesis of (2E)-1-(3,5- Dibromo-4-methoxy phenyl)-3-aryl-prop-2-en-
1-ones
See Part-I, Section-I (C).
(B) Synthesis of 6-(3,5-Dibromo-4-methoxyphenyl)-4-phenyl-3-phenyl-3,4-
dihydro-2H-pyran-1-one
 (2E)-1-(3,5-dibromo-4-methoxyphenyl)-4-phenyl-3-phenyl-prop-2-en-1-one.
(3.96gm, 0.01 mol) and ethyl phenyl acetate (1.64gm, 0.01 mol) were added
successively to a suspension of sodium ethoxide (0.46gm, 0.01 mol) in dry benzene
(50 ml). The reaction mixture was heated on a water-bath for 3 hrs. The reaction
mixture was poured into cold dilute HCl (10%) and extracted with benzene. The
benzene layer was washed with sodium bicarbonate solution, dried and evaporated.
The residue was crystal l ized from methanol.  Yield.60% ; C24H18Br2O3
m.p. 960C Anal. Calcd. for Requires: C, 56.06; H, 3.53; Found: C, 56.16; H,3.59%
Similarly, other 6-(3,5-dibromo-4-methoxyphenyl)-4-aryl-3-phenyl-3,4-dihydro-
2H-pyran-1-ones were prepared. The physical data are recorded in Table No. 13
(C) Biological screening of 6-(3,5-Dibromo-4-methoxyphenyl)-4-aryl-3-
phenyl-3,4-dihydro-2H-pyran-1-ones
Antimicrobial testing were carried out as described in Part-I Section-1(D).
The zones of inhibition of test solutions are recorded in Graphical Chart No. 13
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T = Compounds selected by Tuberculosis Antimicrobial Acquisation Coordinat
ing Facility (TAACF), Southern research institute, Alabama, U.S.A. for antitu-
bercular activity.
